Our Company

Ernest Loumaye, MD, PhD

Co-Founder & CEO – ObsEvaMember, ObsEva Board of Directors

Ernest Loumaye, MD, PhD, OB/GYN has extensive experience in pharma product development and the management of biopharmaceutical companies..

After a brief academic career at Louvain University Hospital, he joined Serono as Head of Clinical Development for Reproductive Health (Geneva and Boston). He contributed actively to the worldwide registration of three important biotechnology products. In 2003, Ernest joined Ipsen in Paris as Vice President, Medical Sciences. In 2006, Ernest co-founded PregLem, a Swiss based specialty biopharmaceutical company. As CEO, he led the company up to the successful European registration of Esmya®, its lead product. The company was acquired by Gedeon Richter Plc. in 2010.

In 2012, Ernest co-founded ObsEva and since then has served as the CEO of the company and as Board Member. Based in Geneva, ObsEva SA (NASDAQ: OBSV / SIX: OBSN) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.

Ernest Loumaye was a visiting Professor of Reproductive Endocrinology at Louvain University, Brussels from 2002 to 2010, where he held a full time clinical and academic position until 1991.

Ernest holds MD, PhD degrees, with a specialization in Obstetrics and Gynaecology from Louvain University, Belgium. He was a research fellow at the National Institute of Child Health and Human Development in the US and is the author of over 90 publications in peer-reviewed journals.

He also currently serves as a Board Member for AVA in Zurich a FEMTECH company.

Are you sure you want to leave ObsEva.com?

We're sorry to see you go.
Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue